Gilead Sciences (GILD) Cash from Investing Activities Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Cash from Investing Activities Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 23.45%
Dec 31, 2025 27.21%
Sep 30, 2025 -9.52%
Jun 30, 2025 15.88%
Mar 31, 2025 -3.82%
Dec 31, 2024 -20.32%
Sep 30, 2024 17.35%
Jun 30, 2024 45.11%
Mar 31, 2024 -55.34%
Dec 31, 2023 -17.77%
Sep 30, 2023 -16.14%
Jun 30, 2023 -15.91%
Mar 31, 2023 -16.97%
Dec 31, 2022 48.16%
Sep 30, 2022 19.54%
Jun 30, 2022 40.83%
Mar 31, 2022 -40.55%
Dec 31, 2021 36.42%
Sep 30, 2021 43.08%
Jun 30, 2021 29.38%